The pressure against pharmacy benefit managers (PBMs) continues to build. On Tuesday, the Federal Trade Commission released ...

The FTC report found that from 2017 to 2022, three PBMs—UnitedHealth Group's Optum, CVS Health's CVS Caremark and Cigna's ...

How do scientists develop new treatments for disease? With Gleevec, a remarkable cancer drug, the approach was to target the disease at the cellular and subcellular level. When people say Gleevec ...

The Federal Trade Commission published a second interim staff report this week on the prescription drug middleman industry, which ...

The patent loss of its biggest earning drug has hit Novartis’ revenues ... Chronic myeloid leukaemia (CML) blockbuster Gleevec has been badly hit by generic competition in the US, revenues ...

UnitedHealthcare's legal drug dealing arm is, according to the government, massively marking up the cost of life-saving ...

FTC report reveals significant markups by top PBMs on specialty drugs, driving $7.3 billion in revenue and raising costs for ...

A report published Tuesday shows hundreds and thousands of percent markups on HIV, hypertension and cancer drugs for Medicare ...

The Federal Trade Commission suggests that PBMs profit from specialty generic drugs such as those for cancer and HIV and ...

The report analyzed all specialty generic drugs dispensed from 2017 ... The analysis included such specialty drugs as Gleevec for leukemia, Ampyra for multiple sclerosis, and Sensipar for kidney ...

Generic cancer drugs are covered more frequently by Part ... Several newly approved drugs, such as Gleevec (imatinib) and Tarceva (erlotinib), are covered nearly universally by Part D plans.